BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28124437)

  • 1. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.
    Wang TF; Chu SC; Lee JJ; Yang GG; Huang WH; Chang ET; Low T; Wu YF; Kao RH; Lin CB
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):304-313. PubMed ID: 28124437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
    Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
    AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
    Zeng Z; Chen HJ; Yan HH; Yang JJ; Zhang XC; Wu YL
    Int J Biol Markers; 2013 Sep; 28(3):249-58. PubMed ID: 23873621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients 
Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis: 
A Single-center Retrospective Study].
    Yin W; Zhang H; Gu Y; Yi F; Li Q; Liu Y; Yao Y; Liu Z; Cao B
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):156-166. PubMed ID: 35340158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.
    Yoshimura A; Yamada T; Tsuji T; Hamashima R; Shiotsu S; Yuba T; Takumi C; Uchino J; Hiraoka N; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):557-563. PubMed ID: 30672656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
    Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
    Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.